Commit Biologics
Copenhagen biotech spun out of Aarhus University, developing the BiCE platform for oncology and autoimmune diseases.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
๐๏ธ Deep Dive
Payhawk, Commit Biologics, Dcubed โ $280M for AI finance, immunotherapy and space hardware โ Daily News November 18, 2026
Listen to the episodeAbout Commit Biologics
Commit Biologics is a Copenhagen biotech spun out of Aarhus University and initially incubated by the BioInnovation Institute. It develops Bispecific Complement Engagers (BiCE), antibodies designed to recruit the complement system, part of innate immunity, against target cells. Its first candidate, COM002, is a dual-targeting molecule for targeted immune cell depletion in patients with cancer and autoimmune disease. Launched in May 2024 with a โฌ16 million seed backed by Novo Holdings and Bioqube Ventures, on 17 November 2026 it completed a $60 million (โฌ54 million) seed financing led by Ackermans & van Haaren, with AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. The money will fund IND-enabling work and the IND filing for COM002, with first patient dosing expected in early 2028, plus a second programme. Its CEO is Thomas L. F. Montgomery Andresen, who joined from T-Cypher Bio in 2026.
The Story
Spun out of Aarhus University, incorporated in 2021 as Commit Biologics ApS and incubated by the BioInnovation Institute; publicly launched in May 2024 with a โฌ16 million seed round.
How Commit Biologics works
Business Model
Biologic drug development, with potential pharmaceutical partnerships.
Products & Services
Key Products
- BiCE platform
- COM002
Core Use Cases
- Oncology
- Autoimmune diseases
- Targeted immune cell depletion
Market & Clients
Key Customers
Patients and, in future, pharmaceutical partners.
Geographic Presence
How Commit Biologics competes
Competitive Advantages
- Targeted complement activation through bispecific antibodies
How Commit Biologics grows
Growth Strategy
Take COM002 to an IND filing and into the clinic and advance a second programme.
Regulatory Context
COM002 must complete IND-enabling work and an IND filing before clinical trials.
Key Risks
- Clinical risk
- Regulatory risk
- Safety and efficacy not yet shown in humans
Strategic Insights
- The round funds the move from a preclinical platform towards the clinic, bringing in two pharma corporate venture investors.
Funding & Investors
Funding Rounds
- 2026 - Seed (final close): $60M (โฌ54M)
Lead: Ackermans & van Haaren - 2024 - Seed: โฌ16M
Key Investors
Founding Team
Key Executives
- Thomas L. F. Montgomery Andresen - CEO
Key Metrics
Lessons from Commit Biologics
- A scientific platform becomes investable when it produces candidates and measurable regulatory milestones.
Similar Startups
Teton.ai
Copenhagen company founded in 2020 with AI for care facilities. On 9 September 2025 it announced a $20 million Series A.
Read AnalysisAdcendo
A clinical-stage Copenhagen biotech developing antibody-drug conjugates (ADCs) for cancers with high unmet need, with three programmes in the clinic.
Read AnalysisNewAmsterdam Pharma
Biopharmaceutical company focused on innovative therapies for hypercholesterolemia and cardiometabolic diseases with breakthrough clinical results.
Read AnalysisSources
- Commit Biologics announces final close of $60 million seed financing — Commit Biologics
- Commit Biologics commits to the clinic with $60m seed round — BioXconomy
- Commit Biologics advances complement platform with โฌ16m seed financing — BioPharma-Reporter
- Commit Biologics ApS โ nรธgletal — Proff